Scarica l'app Stockscreener
2.9985
2.28%
-0.0715
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.07
Aprire:
$3.03
Volume 24 ore:
334.13K
Relative Volume:
0.29
Capitalizzazione di mercato:
$199.26M
Reddito:
$488.00K
Utile/perdita netta:
$-41.44M
Rapporto P/E:
-3.2242
EPS:
-0.93
Flusso di cassa netto:
$-31.47M
1 W Prestazione:
+12.36%
1M Prestazione:
+6.38%
6M Prestazione:
+20.00%
1 anno Prestazione:
-15.25%
Intervallo 1D:
$2.95
$3.03
Intervallo di 1 settimana:
$2.595
$3.08
Portata 52W:
$2.01
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Nome
Cardiff Oncology Inc
Settore
Industria
Telefono
858-952-7570
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Confronta CRDF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.995 | 180.95M | 488.00K | -41.44M | -31.47M | -0.93 |
|
ONC
Beigene Ltd Adr
|
238.24 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.69 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.39 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.60 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.50 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-06 | Iniziato | Craig Hallum | Buy |
| 2022-01-05 | Iniziato | William Blair | Outperform |
| 2021-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-09 | Ripresa | Maxim Group | Buy |
| 2020-10-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
The Manufacturers Life Insurance Company Makes New $67,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Price T Rowe Associates Inc. MD Has $67,000 Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
13,124 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Bought by Voya Investment Management LLC - Defense World
Cardiff Oncology Reports Increased Losses Amid Rising R&D Costs - TipRanks
Raymond James Financial Inc. Purchases New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know - Nasdaq
Cardiff Oncology: Buying The First-Line Onvansertib Strategy (NASDAQ:CRDF) - Seeking Alpha
Barclays PLC Purchases 9,507 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Wells Fargo & Company MN Purchases 8,851 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Mariner LLC Makes New $61,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology stock target raised to $18 by H.C. Wainwright - Investing.com Canada
Cardiff Oncology (CRDF) Gains Analyst Confidence with Price Target Increase | CRDF Stock News - GuruFocus
Cardiff Oncology (CRDF) Price Target Increased by Analyst | CRDF Stock News - GuruFocus
Cardiff Oncology: Q1 Earnings Snapshot - New Haven Register
Cardiff Oncology earnings missed by $0.01, revenue topped estimates - Investing.com Canada
Promising Clinical Trial Developments Drive Buy Rating for Cardiff Oncology - TipRanks
Cardiff Oncology (CRDF) Reports Strong Q1 Revenue and Advances Cancer Therapy | CRDF Stock News - GuruFocus
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Cardiff Oncology Q1 2025 Earnings: EPS Misses at -$0.20, Revenue Slightly Beats at $0.11 Million - GuruFocus
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - GlobeNewswire
Financial Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) and Cardiff Oncology (NASDAQ:CRDF) - Defense World
Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon - Seeking Alpha
Investing in Cardiff Oncology Inc (CRDF) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Analysts review Cardiff Oncology Inc’s rating - knoxdaily.com
Cardiff Oncology Inc Inc. (CRDF) Price Performance: The Role of Supply and Demand - investchronicle.com
Market Highlights: Cardiff Oncology Inc (CRDF) Ends on a High Note at 2.95 - DWinneX
Cardiff Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Purchased by Geode Capital Management LLC - Defense World
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
Cardiff Oncology Inc [CRDF] Records 50-Day SMA of $3.62 - knoxdaily.com
Market Insights: Cardiff Oncology Inc (CRDF)’s Notable Drop of -3.61, Closing at 2.94 - DWinneX
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
A Tale of Resilience: Cardiff Oncology Inc Amid Stock Market Turbulence - investchronicle.com
Cardiff Oncology (CRDF) Secures New U.S. Patent for Cancer Treat - GuruFocus
Cardiff Oncology (CRDF) Secures New U.S. Patent for Cancer Treatment Method | CRDF Stock News - GuruFocus
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - GlobeNewswire
A look into Cardiff Oncology Inc (CRDF)’s deeper side - Sete News
Cardiff Oncology Wins Crucial Patent: Breakthrough Cancer Drug Now Covers All Bevacizumab-Naïve Patients - Stock Titan
A closer look at Cardiff Oncology Inc (CRDF) is warranted - uspostnews.com
Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap touched US$186m last week, benefiting both individual investors who own 56% as well as institutions - simplywall.st
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial i - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing R - GuruFocus
Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment - MarketScreener
Cardiff Oncology Announces Completion of Enrollment in Phase 2 C - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial in Colorectal Cancer | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cardiff Oncology Completes Patient Enrollment in Phase 2 CRDF-004 Trial for RAS-Mutated Metastatic Colorectal Cancer, Additional Data Expected in 1H 2025 - Nasdaq
Cardiff Oncology Awards Strategic Compensation Package: Inside the Latest Employee Stock Options Grant - Stock Titan
Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):